Koskinen Kaisa, Vainio Petri J, Smith David J, Pihlavisto Marjo, Ylä-Herttuala Seppo, Jalkanen Sirpa, Salmi Marko
MediCity Research Laboratory and Department of Medical Microbiology, Turku University. Finland.
Blood. 2004 May 1;103(9):3388-95. doi: 10.1182/blood-2003-09-3275. Epub 2004 Jan 15.
Polymorphonuclear leukocytes (PMNs) migrate from the blood into areas of inflammation by binding to the endothelial cells of blood vessels via adhesion molecules. Vascular adhesion protein-1 (VAP-1) is one of the molecules mediating leukocyte-endothelial cell interactions. It is also an endothelial cell-surface enzyme (amine oxidase) that produces reactive oxygen species during the catalytic reaction. To study the role of the enzymatic activity of VAP-1 in PMN extravasation, we used an enzymatically inactive VAP-1 mutant, specific amine oxidase inhibitors (including a novel small molecule compound), and anti-VAP-1 antibodies in several flow-dependent models. The enzyme inhibitors diminished PMN rolling on and transmigration through human endothelial cells under conditions of laminar shear stress in vitro. Notably, the enzyme inactivating point mutation abolished the capacity of VAP-1 to mediate transmigration. Moreover, the new VAP-1 inhibitor effectively prevented the extravasation of PMNs in an animal model of inflammation. These data show that the oxidase activity of VAP-1 controls PMN exit from the blood during the relatively poorly understood transmigration step.
多形核白细胞(PMN)通过粘附分子与血管内皮细胞结合,从血液迁移到炎症区域。血管粘附蛋白-1(VAP-1)是介导白细胞与内皮细胞相互作用的分子之一。它也是一种内皮细胞表面酶(胺氧化酶),在催化反应过程中产生活性氧。为了研究VAP-1的酶活性在PMN渗出中的作用,我们在几个流动依赖模型中使用了无酶活性的VAP-1突变体、特异性胺氧化酶抑制剂(包括一种新型小分子化合物)和抗VAP-1抗体。在体外层流剪切应力条件下,酶抑制剂减少了PMN在人内皮细胞上的滚动和穿过内皮细胞的迁移。值得注意的是,酶失活点突变消除了VAP-1介导迁移的能力。此外,新型VAP-1抑制剂在炎症动物模型中有效阻止了PMN的渗出。这些数据表明,在相对了解较少的迁移步骤中,VAP-1的氧化酶活性控制着PMN从血液中渗出。